Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Crosses Below 200 Day Moving Average of $6.62

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)’s share price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.62 and traded as low as $4.24. Eagle Pharmaceuticals shares last traded at $4.41, with a volume of 51,307 shares trading hands.

Eagle Pharmaceuticals Stock Performance

The company has a 50 day moving average of $5.21 and a two-hundred day moving average of $6.57. The stock has a market cap of $57.29 million, a PE ratio of 3.74 and a beta of 0.46.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. increased its stake in shares of Eagle Pharmaceuticals by 25.0% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the specialty pharmaceutical company’s stock valued at $7,885,000 after purchasing an additional 100,000 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter valued at about $575,000. Brandes Investment Partners LP increased its stake in shares of Eagle Pharmaceuticals by 34.9% in the 3rd quarter. Brandes Investment Partners LP now owns 1,134,363 shares of the specialty pharmaceutical company’s stock valued at $17,889,000 after purchasing an additional 293,276 shares in the last quarter. DGS Capital Management LLC purchased a new position in shares of Eagle Pharmaceuticals in the 4th quarter valued at about $60,000. Finally, Trexquant Investment LP increased its stake in Eagle Pharmaceuticals by 26.1% during the 3rd quarter. Trexquant Investment LP now owns 67,187 shares of the specialty pharmaceutical company’s stock worth $1,060,000 after buying an additional 13,910 shares in the last quarter. Hedge funds and other institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.